Bladder Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Bladder Cancer – Pipeline Review, H2 2017’, provides an overview of the Bladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects

The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bladder Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Abivax SA

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Altor BioScience Corp

AndroScience Corp

ANP Technologies Inc

APIM Therapeutics AS

Archivel Farma SL

Argos Therapeutics Inc

Arno Therapeutics Inc

Array BioPharma Inc

Asana BioSciences LLC

Asieris Pharmaceuticals Co Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bavarian Nordic A/S

Bayer AG

Biocad

BioCancell Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biomics Biotechnologies Co Ltd

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Celprogen Inc

Celsion Corp

Celyad SA

Cleveland BioLabs Inc

Cold Genesys Inc

Corvus Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Eleven Biotherapeutics Inc

Eli Lilly and Co

Elsalys Biotech SAS

EpiThany Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Gene Signal International SA

Genentech Inc

Genmab A/S

GlaxoSmithKline Plc

H3 Biomedicine Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

HitGen LTD

Horizon Pharma Plc

Immunocore Ltd

Immunomedics Inc

Immupharma Plc

Imugene Ltd

Incanthera Ltd

Incyte Corp

Innovation Pharmaceuticals Inc

InteRNA Technologies BV

Iovance Biotherapeutics Inc

Johnson & Johnson

Kite Pharma Inc

Laboratoires Pierre Fabre SA

LipoMedix Pharmaceutical Inc

Loxo Oncology Inc

Lycera Corp

MacroGenics Inc

Marina Biotech Inc

MaxiVAX SA

Medicenna Therapeutics Corp

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mirati Therapeutics Inc

Moleculin Biotech Inc

MTG Biotherapeutics Inc

NanoCarrier Co Ltd

NantKwest Inc

Nektar Therapeutics

Novartis AG

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Optimum Therapeutics LLC

Oxford BioTherapeutics Ltd

Pfizer Inc

Pharma Mar SA

Philogen SpA

Pieris Pharmaceuticals Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Provecs Medical GmbH (Inactive)

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

Rexahn Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sareum Holdings Plc

Shionogi & Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Sitka Biopharma Inc

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stemline Therapeutics Inc

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Taris Biomedical LLC

Theralase Technologies Inc

Tocagen Inc

Tolero Pharmaceuticals Inc

Transgene SA

UroGen Pharma Ltd

Vaccibody AS

Vakzine Projekt Management GmbH

Vault Pharma Inc

Vaxeal Holding SA

Vaxiion Therapeutics Inc

Viralytics Ltd

Vyriad Inc

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Bladder Cancer - Overview 9

Bladder Cancer - Therapeutics Development 10

Bladder Cancer - Therapeutics Assessment 36

Bladder Cancer - Companies Involved in Therapeutics Development 55

Bladder Cancer - Drug Profiles 112

Bladder Cancer - Dormant Projects 894

Bladder Cancer - Discontinued Products 901

Bladder Cancer - Product Development Milestones 903

Appendix 914

List of Tables

List of Tables

Number of Products under Development for Bladder Cancer, H2 2017 32

Number of Products under Development by Companies, H2 2017 34

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 35

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 36

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 37

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 38

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 39

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 40

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 41

Number of Products under Development by Universities/Institutes, H2 2017 42

Products under Development by Companies, H2 2017 44

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 45

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 46

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 47

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 48

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 49

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 50

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 51

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 52

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 53

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 54

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 55

Products under Development by Universities/Institutes, H2 2017 56

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 57

Number of Products by Stage and Target, H2 2017 59

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 60

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 61

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 62

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 63

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 64

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 65

Number of Products by Stage and Mechanism of Action, H2 2017 67

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 68

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 69

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 70

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 71

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 72

Number of Products by Stage and Route of Administration, H2 2017 74

Number of Products by Stage and Molecule Type, H2 2017 76

Bladder Cancer – Pipeline by 4SC AG, H2 2017 77

Bladder Cancer – Pipeline by Abivax SA, H2 2017 77

Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2017 78

Bladder Cancer – Pipeline by ADC Therapeutics Sarl, H2 2017 78

Bladder Cancer – Pipeline by Altor BioScience Corp, H2 2017 79

Bladder Cancer – Pipeline by AndroScience Corp, H2 2017 79

Bladder Cancer – Pipeline by ANP Technologies Inc, H2 2017 79

Bladder Cancer – Pipeline by APIM Therapeutics AS, H2 2017 80

Bladder Cancer – Pipeline by Archivel Farma SL, H2 2017 80

Bladder Cancer – Pipeline by Argos Therapeutics Inc, H2 2017 81

Bladder Cancer – Pipeline by Arno Therapeutics Inc, H2 2017 81

Bladder Cancer – Pipeline by Array BioPharma Inc, H2 2017 81

Bladder Cancer – Pipeline by Asana BioSciences LLC, H2 2017 82

Bladder Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2017 82

Bladder Cancer – Pipeline by Astellas Pharma Inc, H2 2017 83

Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2017 83

Bladder Cancer – Pipeline by AstraZeneca Plc, H2 2017 84

Bladder Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2017 84

Bladder Cancer – Pipeline by Bavarian Nordic A/S, H2 2017 85

Bladder Cancer – Pipeline by Bayer AG, H2 2017 85

Bladder Cancer – Pipeline by Biocad, H2 2017 86

Bladder Cancer – Pipeline by BioCancell Ltd, H2 2017 86

Bladder Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017 87

Bladder Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 87

Bladder Cancer – Pipeline by Biotest AG, H2 2017 87

Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2017 88

Bladder Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2017 88

Bladder Cancer – Pipeline by Celgene Corp, H2 2017 89

Bladder Cancer – Pipeline by Celldex Therapeutics Inc, H2 2017 90

Bladder Cancer – Pipeline by Celprogen Inc, H2 2017 90

Bladder Cancer – Pipeline by Celsion Corp, H2 2017 90

Bladder Cancer – Pipeline by Celyad SA, H2 2017 91

Bladder Cancer – Pipeline by Cleveland BioLabs Inc, H2 2017 91

Bladder Cancer – Pipeline by Cold Genesys Inc, H2 2017 92

Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc, H2 2017 92

Bladder Cancer – Pipeline by CytomX Therapeutics Inc, H2 2017 93

Bladder Cancer – Pipeline by Cytori Therapeutics Inc, H2 2017 93

Bladder Cancer – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 94

Bladder Cancer – Pipeline by Eisai Co Ltd, H2 2017 94

Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc, H2 2017 95

Bladder Cancer – Pipeline by Eli Lilly and Co, H2 2017 95

Bladder Cancer – Pipeline by Elsalys Biotech SAS, H2 2017 96

Bladder Cancer – Pipeline by EpiThany Inc, H2 2017 96

Bladder Cancer – Pipeline by Esperance Pharmaceuticals Inc, H2 2017 96

Bladder Cancer – Pipeline by Exelixis Inc, H2 2017 97

Bladder Cancer – Pipeline by Exicure Inc, H2 2017 97

Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 98

Bladder Cancer – Pipeline by Five Prime Therapeutics Inc, H2 2017 98

Bladder Cancer – Pipeline by Gene Signal International SA, H2 2017 99

Bladder Cancer – Pipeline by Genentech Inc, H2 2017 99

Bladder Cancer – Pipeline by Genmab A/S, H2 2017 99

Bladder Cancer – Pipeline by GlaxoSmithKline Plc, H2 2017 100

Bladder Cancer – Pipeline by H3 Biomedicine Inc, H2 2017 100

Bladder Cancer – Pipeline by Hamlet Pharma AB, H2 2017 101

Bladder Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 101

Bladder Cancer – Pipeline by HitGen LTD, H2 2017 102

Bladder Cancer – Pipeline by Horizon Pharma Plc, H2 2017 102

Bladder Cancer – Pipeline by Immunocore Ltd, H2 2017 102

Bladder Cancer – Pipeline by Immunomedics Inc, H2 2017 103

Bladder Cancer – Pipeline by Immupharma Plc, H2 2017 103

Bladder Cancer – Pipeline by Imugene Ltd, H2 2017 104

Bladder Cancer – Pipeline by Incanthera Ltd, H2 2017 104

Bladder Cancer – Pipeline by Incyte Corp, H2 2017 105

Bladder Cancer – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 105

Bladder Cancer – Pipeline by InteRNA Technologies BV, H2 2017 106

Bladder Cancer – Pipeline by Iovance Biotherapeutics Inc, H2 2017 106

Bladder Cancer – Pipeline by Johnson & Johnson, H2 2017 107

Bladder Cancer – Pipeline by Kite Pharma Inc, H2 2017 107

Bladder Cancer – Pipeline by Laboratoires Pierre Fabre SA, H2 2017 108

Bladder Cancer – Pipeline by LipoMedix Pharmaceutical Inc, H2 2017 108

Bladder Cancer – Pipeline by Loxo Oncology Inc, H2 2017 108

Bladder Cancer – Pipeline by Lycera Corp, H2 2017 109

Bladder Cancer – Pipeline by MacroGenics Inc, H2 2017 109

Bladder Cancer – Pipeline by Marina Biotech Inc, H2 2017 110

Bladder Cancer – Pipeline by MaxiVAX SA, H2 2017 110

Bladder Cancer – Pipeline by Medicenna Therapeutics Corp, H2 2017 110

Bladder Cancer – Pipeline by MedImmune LLC, H2 2017 111

Bladder Cancer – Pipeline by Merck & Co Inc, H2 2017 112

Bladder Cancer – Pipeline by Merck KGaA, H2 2017 112

Bladder Cancer – Pipeline by Mirati Therapeutics Inc, H2 2017 113

Bladder Cancer – Pipeline by Moleculin Biotech Inc, H2 2017 113

Bladder Cancer – Pipeline by MTG Biotherapeutics Inc, H2 2017 113

Bladder Cancer – Pipeline by NanoCarrier Co Ltd, H2 2017 114

Bladder Cancer – Pipeline by NantKwest Inc, H2 2017 114

Bladder Cancer – Pipeline by Nektar Therapeutics, H2 2017 115

Bladder Cancer – Pipeline by Novartis AG, H2 2017 115

Bladder Cancer – Pipeline by OncoTherapy Science Inc, H2 2017 116

Bladder Cancer – Pipeline by Oncovir Inc, H2 2017 116

Bladder Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 117

Bladder Cancer – Pipeline by Optimum Therapeutics LLC, H2 2017 117

Bladder Cancer – Pipeline by Oxford BioTherapeutics Ltd, H2 2017 117

Bladder Cancer – Pipeline by Pfizer Inc, H2 2017 118

Bladder Cancer – Pipeline by Pharma Mar SA, H2 2017 118

Bladder Cancer – Pipeline by Philogen SpA, H2 2017 119

Bladder Cancer – Pipeline by Pieris Pharmaceuticals Inc, H2 2017 119

Bladder Cancer – Pipeline by Plexxikon Inc, H2 2017 120

Bladder Cancer – Pipeline by Polaris Pharmaceuticals Inc, H2 2017 120

Bladder Cancer – Pipeline by Provecs Medical GmbH (Inactive), H2 2017 120

Bladder Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 121

Bladder Cancer – Pipeline by PsiOxus Therapeutics Ltd, H2 2017 121

Bladder Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 122

Bladder Cancer – Pipeline by Samyang Holdings Corp, H2 2017 122

Bladder Cancer – Pipeline by Sanofi, H2 2017 123

Bladder Cancer – Pipeline by Sareum Holdings Plc, H2 2017 123

Bladder Cancer – Pipeline by Shionogi & Co Ltd, H2 2017 124

Bladder Cancer – Pipeline by Sierra Oncology Inc, H2 2017 124

Bladder Cancer – Pipeline by Sillajen Biotherapeutics, H2 2017 124

Bladder Cancer – Pipeline by Sitka Biopharma Inc, H2 2017 125

Bladder Cancer – Pipeline by Sorrento Therapeutics Inc, H2 2017 125

Bladder Cancer – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 126

Bladder Cancer – Pipeline by Stemline Therapeutics Inc, H2 2017 126

Bladder Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 127

Bladder Cancer – Pipeline by Taiwan Liposome Company Ltd, H2 2017 127

Bladder Cancer – Pipeline by Taris Biomedical LLC, H2 2017 128

Bladder Cancer – Pipeline by Theralase Technologies Inc, H2 2017 128

Bladder Cancer – Pipeline by Tocagen Inc, H2 2017 129

Bladder Cancer – Pipeline by Tolero Pharmaceuticals Inc, H2 2017 129

Bladder Cancer – Pipeline by Transgene SA, H2 2017 129

Bladder Cancer – Pipeline by UroGen Pharma Ltd, H2 2017 130

Bladder Cancer – Pipeline by Vaccibody AS, H2 2017 130

Bladder Cancer – Pipeline by Vakzine Projekt Management GmbH, H2 2017 131

Bladder Cancer – Pipeline by Vault Pharma Inc, H2 2017 131

Bladder Cancer – Pipeline by Vaxeal Holding SA, H2 2017 131

Bladder Cancer – Pipeline by Vaxiion Therapeutics Inc, H2 2017 132

Bladder Cancer – Pipeline by Viralytics Ltd, H2 2017 132

Bladder Cancer – Pipeline by Vyriad Inc, H2 2017 133

Bladder Cancer – Pipeline by Zymeworks Inc, H2 2017 133

Bladder Cancer – Dormant Projects, H2 2017 916

Bladder Cancer – Dormant Projects, H2 2017 (Contd..1), H2 2017 917

Bladder Cancer – Dormant Projects, H2 2017 (Contd..2), H2 2017 918

Bladder Cancer – Dormant Projects, H2 2017 (Contd..3), H2 2017 919

Bladder Cancer – Dormant Projects, H2 2017 (Contd..4), H2 2017 920

Bladder Cancer – Dormant Projects, H2 2017 (Contd..5), H2 2017 921

Bladder Cancer – Dormant Projects, H2 2017 (Contd..6), H2 2017 922

Bladder Cancer – Discontinued Products, H2 2017 923

Bladder Cancer – Discontinued Products, H2 2017 (Contd..1), H2 2017 924

List of Figures

List of Figures

Number of Products under Development for Bladder Cancer, H2 2017 32

Number of Products under Development by Companies, H2 2017 33

Number of Products under Development by Universities/Institutes, H2 2017 42

Number of Products by Top 10 Targets, H2 2017 58

Number of Products by Stage and Top 10 Targets, H2 2017 58

Number of Products by Top 10 Mechanism of Actions, H2 2017 66

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 66

Number of Products by Routes of Administration, H2 2017 73

Number of Products by Stage and Routes of Administration, H2 2017 73

Number of Products by Top 10 Molecule Types, H2 2017 75

Number of Products by Stage and Top 10 Molecule Types, H2 2017 75

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports